Multidrug resistant tuberculosis: prevalence and risk factors in districts of metema and west armachiho, Northwest Ethiopia
Open Access
- 26 October 2015
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 15 (1) , 1-6
Abstract
Multi drug resistant tuberculosis (MDR-TB) is an emerging challenge for TB control programs globally. According to World health organization, 2012 report Ethiopia stands 15th out of the 27 high priority countries in the world and 3rd in Africa. Updated knowledge of the magnitude of MDR-TB is so substantial to allocate resources, and to address prevention and control measures. Therefore, the aim of this study was to assess the prevalence of MDR-TB and associated risk factors in West Armachiho and Metema districts of North Gondar. A cross-sectional study was conducted in West Armachiho and Metema districts between February 01 and June 25, 2014. A total of 124 consecutive smear positive pulmonary tuberculosis patients were included in the study. Socio-demographic and possible risk factor data were collected using a semi-structured questionnaire. Drug susceptibility testing was first performed for rifampicin using GeneXpert MTB/RIF. For those rifampicin resistant strains, drug susceptibility testing was performed for both isoniazid and rifampicin to identify MDR-TB using the proportional method on LJ media. Data were analyzed using statistical Package SPSS version 20; binary logistic regression was used to assess the association. P-values < 0.05 were considered as statistically significant. Of 124 smear-positive pulmonary TB patients, 117 (94.4 %) were susceptible to Rifampicin, while 7 (5.7 %) were confirmed to be resistant to Rifampicin and Isoniazid. The overall prevalence of MDR-TB was 5.7 % (2.3 % among new cases and 13.9 % among previously treated cases). History of previous treatment (OR = 7, P = 0.025) was significantly associated risk factor for MDR-TB. The overall prevalence of MDR-TB was 5.7 % among cases at five health centers and a history of previous treatment was found to be a risk factor for being infected by an MDR-TB strain. Therefore, maximizing early case detection and treatment, strengthening TB infection control activities and proper implementation of DOTS are recommended to reduce the burden of MDR-TB.Keywords
This publication has 14 references indexed in Scilit:
- Drug resistance patterns of Mycobacterium tuberculosis complex and associated factors among retreatment cases around Jimma, Southwest EthiopiaBMC Public Health, 2015
- Prevalence and drug resistance profile of Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients attending two public hospitals in East Gojjam zone, northwest EthiopiaBMC Public Health, 2015
- Prevalence of Tuberculosis, Drug Susceptibility Testing, and Genotyping of Mycobacterial Isolates from Pulmonary Tuberculosis Patients in Dessie, EthiopiaTuberculosis Research and Treatment, 2015
- Multidrug-resistant tuberculosis in Ethiopia: efforts to expand diagnostic services, treatment and careAntimicrobial Resistance & Infection Control, 2014
- Determinants of multidrug-resistant tuberculosis in patients who underwent first-line treatment in Addis Ababa: a case control studyBMC Public Health, 2013
- Review of multidrug-resistant and extensively drug-resistant TB: global perspectives with a focus on sub-Saharan AfricaTropical Medicine & International Health, 2010
- Antimicrobial Resistance in Gram-Negative Bacteria from Developing Countries2009
- Risk factors for acquired multidrug-resistant tuberculosisJornal de Pneumologia, 2003
- Molecular Epidemiology and Drug Resistance of Mycobacterium tuberculosis Isolates from Ethiopian Pulmonary Tuberculosis Patients with and without Human Immunodeficiency Virus InfectionJournal of Clinical Microbiology, 2002
- Sensitivity to Anti-tuberculosis Drugs in HIV-positive and -negative Patients in Addis AbabaScandinavian Journal of Infectious Diseases, 2001